CRSP

Crispr Therapeutics Stock Analysis

AI Rating

Low
  • Quality0/10
  • Growth↓ 1/10
  • Momentum↑ 6/10
Crispr Therapeutics sales and earnings growth
CRSP Growth
Low
  • Revenue Y/Y↓ -90.59%
  • EPS Y/Y↓ -49.08%
  • FCF Y/Y↓ -139.11%
Crispr Therapeutics gross and profit margin trends
CRSP Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -16569.80%
  • ROIC↓ -29.00%
Crispr Therapeutics net debt vs free cash flow
CRSP Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Crispr Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗